Skip to content

Menu

About CLTI
Technology
- Products
Clinical Evidence
U.S. Clinical Trial
Company
- Management
- Clinical Advisors
- News
- Media
- Articles
Contact
International

June 6 2017

Midterm Outcomes From a Pilot Study
of Percutaneous Deep Vein Arterialization
for the Treatment of No-Option
Critical Limb Ischemia

View the article.

LimFlow Expands Senior Management Team and Opens Silicon Valley Office LimFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study

Related Posts

LIMFLOW RAISES $40 MILLION (€36 MILLION) IN SERIES D FINANCING

US PIVOTAL STUDY AND CLARITI COMPLETE ENROLLMENT

LATE-BREAKING DATA FROM PROMISE I STUDY ON LIMFLOW SYSTEM CONFIRM EXCELLENT SUSTAINED OUTCOMES IN PATIENTS WITH NO-OPTION CHRONIC LIMB-THREATENING ISCHEMIA

Recent Posts

LIMFLOW RAISES $40 MILLION (€36 MILLION) IN SERIES D FINANCING
US PIVOTAL STUDY AND CLARITI COMPLETE ENROLLMENT
LATE-BREAKING DATA FROM PROMISE I STUDY ON LIMFLOW SYSTEM CONFIRM EXCELLENT SUSTAINED OUTCOMES IN PATIENTS WITH NO-OPTION CHRONIC LIMB-THREATENING ISCHEMIA
THE LIMFLOW SYSTEM FOUND TO BE COST-EFFECTIVE, ACCORDING TO THE NEWEST STUDY PUBLISHED IN THE JOURNAL OF CRITICAL LIMB ISCHEMIA
PUBLICATION OF ONE YEAR OUTCOMES FROM PROMISE I U.S. STUDY OF THE LIMFLOW SYSTEM DEMONSTRATES EXCELLENT SUSTAINED AMPUTATION-FREE SURVIVAL AND WOUND HEALING IN PATIENTS WITH NO-OPTION CHRONIC LIMB-THREATENING ISCHEMIA

CAUTION: Investigational device. Limited by Federal law to investigational use.:

The LimFlow System is approved for sale in markets regulated by the CE Mark.

©2020-present LimFlow SA | Site designed by The Deciding Factor, Inc.